The effects of combination chemotherapy with 5FU and BCNU on rats with dimethylhydrazine (DMH)-induced colon cancer were investigated in a long term survival study. Eighty Wistar rats received a colon cancer producing regimen on DMH (40 mg/kg body weight/week, subcutaneously for 10 weeks). After presenting with signs of colonic disease, all rats underwent diagnostic laparotomy and colonoscopy when colon tumours were located, measured and the extent of the disease staged. Only animals with tumours (n=63) were included and allocated to one of three tumour stages. Stage A (n=17), had colonic tumours without serosal involvement; stage B (n=28) had serosal involvement without metastases; stage C (n= 18) had serosal involvement with lymphadenopathy and/or metastases. Each group was randomly allocated into two subgroups, one serving as untreated controls while the other received 5FU (300 mg/m2 weekly intragastrically for life) together with BCNU (40 mg/m2 intraperitoneally on days 0, 42 and 84). The effect of chemotherapy on tumour growth was measured sequentially by colonoscopy. Animals were observed until death and necropsied, when colon carcinoma was histologically confirmed and survival analysed. The results indicate that chemotherapy significantly prolongs the survival of rats with the least advanced disease (stage A) but was of no benefit to rats with locally advanced or metastatic disease (stages B and C). Furthermore, chemotherapy was associated with a significant reduction in tumour size. Survival analyses in untreated animals show that the laparotomy staging system adopted provides accurate prognostic information. This study shows that DMH-induced colon tumours are chemosensitive, and suggests that this animal model may be a valuable testing ground for new chemotherapeutic agents.
The overall prognosis for patients with colorectal cancer has remained unchanged for several decades, despite advances in diagnosis and treatment.' As surgery is the established form of primary treatment, much research is now directed towards the development of adjuvant methods of treatment such as chemotherapy. Chemotherapeutic research to date, however, has largely involved clinical trials of empirical cytotoxic drug regimens on patients with advanced disease, and these studies have generally been unsuccessful.2 Such observations suggest that there is a need for more fundamental biological information on the effects of chemotherapy on colorectal carcinoma under controlled laboratory conditions. Progress would undoubtedly be facilitated by the availability of suitable animal models of colorectal carcinoma in which chemotherapeutic regimens could be developed and tested before their clinical application.
Two experimental approaches to the chemotherapy of colorectal cancer are currently available. The first utilises human colon tumour xenografts in Danzi, Lewin, Cruse, and Clark immunodeficient mice,25 while the second is a syngeneic system in which colon tumours induced in mice by a chemical carcinogen (1,2- dimethylhydrazine, DMH) are serially transplanted into murine hosts which then receive chemotherapy. '8 In neither of these models are the tumours autochthonous to the host or even sited in the gastrointestinal tract, and the relevance of such systems to the human situation is debatable.
Sych et al9 have recently investigated the chemotherapeutic sensitivity of a number of autochthonous rodent primary colon cancer models induced by a variety of chemical carcinogens. Their report indicates that colon tumours induced in rats by DMH are the most susceptible to cytotoxic agents. As the DMH model is known to closely parallel the human disease in terms of disease presentation, gross, and microscopic pathologyl0 and immunobiology, 1 it was anticipated that DMHinduced colon tumours in rats would respond to chemotherapeutic drugs used in man.
The most promising chemotherapy regimens for human colorectal cancer involve combinations of fluorinated pyrimidines and nitrosoureas.1 2 The current study was accordingly undertaken to evaluate the effects of 5-fluorouracil (5FU) and 1,3-bis (2-chloro-ethyl)-1-nitrosourea (BCNU) on the survival of rats with DMH-induced colon tumours and on the growth of the induced tumours.
Methods

MATERIALS
The experimental design is summarised in Figure 1 By the 19th week, the majority of animals were exhibiting signs of colonic disease and all rats then had a staging laparotomy and diagnostic colonoscopy under nitrous oxide and halothane anaesthesia. At laparotomy the bowel was palpated (without opening), the location and size of colonic tumours recorded and the presence of serosal tethering noted. The abdominal cavity was examined for evidence of metastases (to lymph nodes, omentum, peritoneum, and liver).-Only animals with visible and palpable colonic tumours (n=63) were included in the study.
Under the same anaesthetic, colonoscopy was performed using an Olympus fibreoptic paediatric bronchoscope. The bronchoscope carried, on its distal end, a wire loop with two cross wires of known dimensions. In each animal the index tumour was located and its exact distance from the anal verge measured. This was to ensure that the individual index tumour in each animal could be identified at subsequent colonoscopies and at necropsy. Each index tumour also had its two maximum perpendicular diameters measured using thXe wire loop. Tumour areas were calculated from these measurements using the formula for surface area of an ellipse (nrrr2).
The 63 animals with visible and palpable colon tumours were allocated to one of three tumour stages according to the macroscopic assessment of the largest and most advanced colonic tumour in each animal (the index tumour). Stage A rats (n=17) had index tumours with no visible signs of serosal involvement; stage B (n=28) index tumours showed serosal involvement with puckering and dimpling but no evidence of extracolonic metastases; stage C (n= 18) had index tumours with serosal involvement together with regional lymphadenopathy and/or distant metastases (to omentum, 
Results
The data were analysed after the last rat had died, 240 days after the staging laparotomy and are summarised in Figure 2 
Discussion
The salient finding to emerge from this study is that DMH-induced colon cancer in rats is responsive to chemotherapy with agents used clinically in man. The combination of 5FU and BCNU is successful in Two additional experimental observations are of interest. The first is that the use of fibreoptic colonoscopy as developed in this experiment provides an excellent method of diagnosing and sequentially measuring the effect of chemotherapy on the induced colon tumours. Although colonoscopy has been used for tumour diagnosis in an animal colon cancer model,23 the sequential assessment of the effect of chemotherapy on colon tumour growth in vivo has not hitherto been possible. Secondly, the laparotomy staging system adopted in this experiment, which is analagous to the Duke's staging system for human colorectal cancer24 provides accurate prognostic information.
In other words, animals with less advanced disease (stage A) survive significantly longer than those with more advanced disease (stages B and C), irrespective of treatment. This is in agreement with the findings of Sych et a19 and indicates that the survival of rats with colon cancer closely parallels that of humans with this disease in being dependent upon the extent of disease at the time of diagnosis.
The 
